Obesity: Which drug and when?

International Journal of Clinical Practice

Volumn 61, Issue 9, 2007, Pages 1555-1560

  Lean, M ^a   Mullan, A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYCLOSPORIN; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; WARFARIN;

AGITATION; AWARENESS; BARIATRIC SURGERY; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; LITERATURE; LOW DRUG DOSE; NAUSEA; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; PULSE RATE; REVIEW; SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BODY MASS INDEX; EXERCISE; HUMANS; OBESITY; WEIGHT LOSS;

EID: 34547752964     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01459.x     Document Type: Review

References (33)

1. Zaninotto P, Wardle H, Stamatakis E et al. Joint Health Surveys Unit National Centre for Social Research and Department of Epidemiology and Public Health at the Royal Free and University College Medical School. Forecasting obesity to 2010. London : Department of Health, 2006.
2. Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004 351 : 2683 93.
3. Dixon J. Survival advantage with bariatric surgery: report from the 10th International Congress on Obesity. Surg Obes Relat Dis 2006 2 : 585 6.
4. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992 1 (Suppl. 55 309S 13.
5. Lean MEJ. How does sibutramine work?. IJO 2001 4 (Suppl. 25 S8 11.
6. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 2006 60 : 1697 706.
7. Lean MEJ, Finer N. ABC of obesity: Management: part II - drugs. BMJ 2006 333 : 794 7.
8. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products used in weight control, 2006.
9. Division of Metabolic and Endocrine Drug Products, Food and Drug Administration. Guidance for the clinical evaluation of weight-control drugs, 1997.
10. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003 4 : CD004094.
11. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27 : 155 61.
12. James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000 356 : 2119 25.
13. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomised controlled trial. JAMA 2006 295 : 761 75.
14. Scheen AJ, Finer N, Hollander P et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 368 : 1660 72.
15. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 353 : 2121 34.
16. Van Gaal L, Rissanen AM, Scheen AJ et al. Effects of the cannabionoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365 : 1389 97.
17. Sharma AM. Sibutramine in overweight/obese hypertensive patients. IJO 2001 4 (Suppl. 25 S20 3.
18. Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res 2001 9 : 188 95.
19. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J Suppl 2005 7 : L32 8.
20. Clinical Trials Gov., 2006.
21. James WP. The SCOUT study: risk benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl 2005 7L : L44 8.
22. Zhi J, Melia AT, Eggers H et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995 35 : 1103 8.
23. Zhi J, Moore R, Kanitra L et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002 42 : 1011 9.
24. Zhi J, Moore R, Kanitra L et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxteine and simvastatin) in healthy volunteers. J Clin Pharmacol 2003 43 : 428 35.
25. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003 37 : 510 2.
26. McDuffie JR, Calis KA, Booth SL et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002 22 : 814 22.
27. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996 36 : 647 53.
28. Finer N, James WP, Kopelman PG et al. One-year randomised, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. IJO 2000 24 : 306 13.
29. Scholze J, Grimm E, Herrmann D et al. Optimal treatment of obesity-related hypertension. The Hypertension-Obesity-Sibutramine (HOS) Study. Circulation 2007 115 : 1991 8.
30. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002 440 : 119 28.
31. The Counterweight Project Team. A new evidence-based mode for weight management in primary care: the Counterweight Programme. J Hum Nutr Diet 2004 17 : 191 208.
32. Lamotte M, Annemans L, Lefever A et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002 25 : 303 8.
33. Finer N, Ryan DH, Renz CL et al. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006 8 : 206 13.